THIS ANNOUNCEMENT CONTAINS INSIDE
INFORMATION AS STIPULATED UNDER THE UK VERSION OF THE MARKET ABUSE
REGULATION NO 596/2014 WHICH IS PART OF ENGLISH LAW BY VIRTUE OF
THE EUROPEAN (WITHDRAWAL) ACT 2018, AS AMENDED. ON
PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION
SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC
DOMAIN.
BIVICTRIX THERAPEUTICS
PLC
("BiVictriX" or the
"Company")
Grant of
Options
PDMR/Director
Dealings
Alderley Park, 13 August 2024 - BiVictriX Therapeutics plc (AIM: BVX), a drug discovery
and development company applying an innovative, proprietary
approach to develop a new class of highly selective,
next generation cancer therapeutics, bispecific antibody drug
conjugates (Bi-Cygni® ADCs), which exhibit superior
potency, whilst reducing treatment-related toxicities, announces a
grant of options over an aggregate of 2,717,776 ordinary shares of
1 pence each in the capital of the Company (the "Options") to
certain Directors/PDMRs of the Company.
The Options have an exercise price
of 13 pence each, and will either vest over three years, or be
subject to the achievement of strategic corporate and financial
goals that the Board believes will create value for Shareholders.
The Options will expire ten years from the date of
grant.
The Options have been awarded upon
the recommendation of the Company's Remuneration Committee and
pursuant to the terms of the Company's Share Option Plan, which was
updated and adopted on 28 March 2024.
As part of this review and grant of
Options, 1,032,667 of Tiffany Thorn's previously awarded options,
which were awarded at the time of the IPO in August 2021, and were
aligned to performance criteria, have subsequently been cancelled
due to the performance conditions assigned to them no longer being
regarded as appropriate for the business.
The following Options have
been granted to Directors/PDMRs of the Company:
|
Director/PDMR
|
New Options
granted
|
Options
Cancelled
|
Total Options
held
|
|
Tiffany Thorn
|
2,197,776
|
1,032,667
|
6,862,109
|
|
Susan Lowther
|
200,000
|
-
|
200,000
|
|
Oliver Schon
|
320,000
|
-
|
1,136,333
|
Following this grant of Options, the
total number of ordinary shares under option
is 11,113,443, representing 13.5 per cent. of the
Company's total issued share capital.
|
For
more information, please contact:
|
BiVictriX Therapeutics plc
|
|
|
|
Tiffany Thorn, Chief Executive
Officer
Michael Kauffman, Non-Executive
Chairman
|
Email: info@bivictrix.com
|
|
|
|
|
|
|
SP
Angel Corporate Finance LLP (NOMAD and Broker)
|
Tel: +44 (0) 20 3470
0470
|
|
|
David Hignell, Caroline
Rowe (Corporate Finance)
Vadim Alexandre, Rob Rees (Sales and
Broking)
|
|
|
|
Panmure Liberum Limited (Joint Broker)
|
Tel: +44 (0) 20 7886
2500
|
|
|
Rupert Dearden/Freddy Crossley/Emma
Earl
ICR
Consilium
|
|
|
|
Namrata Taak, Lucy
Featherstone,
Max Bennett, Emmalee Hoppe
|
Tel: +44 (0) 20 3709 5700
Email: Bivictrix@consilium-comms.com
|
|
|
|
|
|
|
|
About BiVictriX Therapeutics plc
BiVictriX is a UK-based drug
discovery and development company which is focused on leveraging
clinical experience to develop a new class of highly selective,
next generation cancer therapeutics which exhibit superior potency,
whilst significantly reducing treatment-related
toxicities.
The Company utilises a
first-in-class approach to generate a proprietary pipeline of
Bi-Cygni® Antibody Drug Conjugate therapeutics which are designed
to selectively target cancer-specific antigen pairs, or "Bi-Cygni®
fingerprints", on tumour cells, which are largely absent from
healthy cells.
BiVictriX has established a growing
proprietary library of cancer-specific Bi-Cygni® fingerprints,
which enable the Company to target a diverse array of different
cancer types. The Company utilises these novel Bi-Cygni®
fingerprints, together with the Company's novel Antibody Drug
Conjugate therapeutic design, to develop more effective and safer
therapeutics to target cancers that are expected to constitute
orphan indications and areas of high unmet medical need.
Find out more about BiVictriX online
at www.bivictrix.com
Notification and public disclosure of transactions by persons
discharging managerial responsibilities and persons closely
associated with them.
|
1.
|
Details of the person discharging managerial responsibilities
/ person closely associated
|
|
a)
|
Name
|
1) Tiffany
Thorn
2) Susan Lowther
3) Oliver Schon
|
|
2.
|
Reason for the Notification
|
|
a)
|
Position/status
|
1) CEO
2) Non-Executive Director
3) VP,
R&D
|
|
b)
|
Initial
notification/Amendment
|
Initial notification
|
|
3.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
BiVictriX Therapeutics plc
|
|
b)
|
LEI
|
213800ZI85IZNA6N3L53
|
|
4.
|
Details of the transaction(s): section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii) each
date; and (iv) each place where transactions have been
conducted
|
|
a)
|
Description of the Financial
instrument, type of instrument
|
Ordinary Shares of 1 pence
each
GB00BNXH3K91
|
|
Identification code
|
|
|
b)
|
Nature of the transaction
|
Grant of Options
|
|
c)
|
Price(s) and volume(s)
|
All Options have an exercise price of
13 pence each
|
Volume of Options
|
|
1 ) 2,197,776
2) 200,000
3) 320,000
|
|
|
d)
|
Aggregated information:
- Aggregated
volume
- Price
|
Volume: 2,717,776 Options
Exercise price of all Options: 13
pence each
|
|
e)
|
Date of the transaction
|
13
August 2024
|
|
f)
|
Place of the transaction
|
Outside a trading venue
|